{"filings":[{"id":452963,"accession_number":"0001789769-26-000044","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2026-05-15T12:30:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Instil Bio reports Q1 2026 cash of $74.7M, GAAP net loss per share $0.62","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, restricted cash and marketable securities $74.7M as of March 31, 2026; expected to fund operations beyond 2027.","GAAP net loss per share $0.62; non-GAAP net loss per share $0.32 for Q1 2026.","R&D expenses $0.7M (down from $5.4M YoY); G&A expenses $5.3M (down from $9.1M).","Company actively evaluating potential acquisitions and in-licensing opportunities for novel therapeutic candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95476,"accession_number":"0001789769-26-000024","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Instil Bio replaces Deloitte with RSM as independent auditor for FY 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Deloitte & Touche LLP effective April 1, 2026; appointed RSM US LLP for fiscal year ending Dec 31, 2026.","Deloitte's reports for 2025 and 2024 were unqualified; no disagreements or reportable events.","No prior consultations with RSM on accounting principles or audit opinions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108585,"accession_number":"0001789769-26-000018","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Instil Bio discontinues AXN-2510, pivots to acquisitions; cash $76.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued clinical development of AXN-2510; terminated license with ImmuneOnco.","Cash, equivalents & marketable securities $76.3M as of Dec 31, 2025, down from $115.1M year-end 2024.","Management evaluating acquisitions and in-licensing opportunities across therapeutic areas.","Net loss per share (GAAP) $1.21 for Q4 2025; full year net loss $10.70 per share.","Cash expected to fund operating plan beyond 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108584,"accession_number":"0001789769-26-000004","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Instil Bio subsidiary terminates license deal with ImmuneOnco for AXN-2510 and AXN-27M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Axion Bio (Instil Bio subsidiary) terminated License and Collaboration Agreement with ImmuneOnco effective Jan 5, 2026.","Agreement, dated Aug 1, 2024, granted Axion ex-China rights to AXN-2510 and AXN-27M.","No details provided on termination reason or financial impact on Instil Bio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125029,"accession_number":"0001789769-25-000092","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Instil Bio reports Q3 net loss $2.01/share; first patient dosed in Phase 1 trial of AXN-2510","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash position $83.4M as of Sept 30, 2025, down from $115.1M at Dec 31, 2024; expects runway beyond 2026.","First patient dosed in Phase 1 trial of AXN-2510/IMM2510 monotherapy in advanced solid tumors in October 2025.","R&D expenses $9.1M in Q3 2025 vs $0.6M in Q3 2024; reflecting increased clinical activity.","Net loss per share (GAAP) $2.01 in Q3 2025 vs $3.54 in Q3 2024; non-GAAP net loss $1.75 vs $2.55."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141722,"accession_number":"0001789769-25-000079","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Instil Bio Q2 net loss $3.24/share; cash $103.6M; IND cleared for '2510","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, marketable securities and long-term investments of $103.6M as of June 30, 2025; funded beyond 2026.","Net loss per share $3.24 (GAAP) and $2.88 (non-GAAP) for Q2 2025, vs $2.29 and $1.57 year-ago.","R&D expenses $6.7M in Q2 2025; in-process R&D expenses $10.0M; G&A expenses $6.2M.","U.S. IND for AXN-2510/IMM2510 cleared; U.S. trial initiation expected before end of 2025.","Appointed Jamie Freedman, M.D., Ph.D. as Chief Medical Officer in June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141721,"accession_number":"0001789769-25-000074","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ImmuneOnco reports 62% partial response rate in Phase 2 NSCLC trial of IMM2510 + chemo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of July 1, 2025, 33 patients dosed at 10 mg/kg; 21 efficacy-evaluable patients.","Partial responses in 62% of evaluable: 80% (8/10) squamous NSCLC, 46% (5/11) non-squamous.","No dose-limiting toxicities; only one TRAE leading to drug discontinuation; low-grade irAEs.","ImmuneOnco expects to present full data at a future medical conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159626,"accession_number":"0001789769-25-000062","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Instil Bio stockholders elect Bronson Crouch as director, ratify Deloitte","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bronson Crouch elected Class I director with 4,662,952 votes for, 281,585 withheld, 927,396 broker non-votes.","Deloitte & Touche LLP ratified as independent auditor for FY2025: 5,862,181 for, 8,649 against, 1,103 abstentions.","Meeting held May 28, 2025; 89.5% of outstanding shares (5,871,933 of 6,558,927) present or represented by proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159625,"accession_number":"0001789769-25-000059","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Instil Bio and ImmuneOnco report Phase 2 NSCLC trial of IMM2510 on track; initial data expected 2H 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial of IMM2510 + chemo in first-line NSCLC in China to complete enrollment of ~60 patients by Q3 2025.","Initial safety and efficacy results from the Phase 2 trial anticipated in second half of 2025.","ORR of 23.1% observed in Phase 1 monotherapy for relapsed/refractory NSCLC (efficacy evaluable n=13).","US Phase 1b/2 monotherapy dose optimization trial of IMM2510 expected to start before end of 2025, subject to regulatory approvals.","Phase 3 trial of IMM2510 + chemo in first-line NSCLC anticipated to start in mid-2026 in China, pending regulatory discussions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159624,"accession_number":"0001789769-25-000054","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Instil Bio releases May 2025 corporate presentation with no material updates","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed under Regulation FD as a routine investor deck; no specific financial or operational metrics disclosed.","Presentation dated May 2025 covers general business overview but lacks new guidance or material events.","No earnings, M&A, leadership changes, or other material disclosures in the filing or exhibit text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159623,"accession_number":"0001789769-25-000050","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Instil Bio Q1 net loss $4.32/share; restructuring charges $16.1M; cash $111.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $4.32 (GAAP) vs $3.74 YoY; non-GAAP $1.32 vs $2.39.","Cash and investments $111.8M, down from $115.1M at Dec 31, 2024; runway beyond 2026.","Restructuring & impairment charges $16.1M vs $4.3M YoY; R&D $5.4M, G&A $9.1M.","AXN-2510/IMM2510 China trial ongoing; initial 1L NSCLC data expected 2H 2025.","U.S. clinical study of AXN-2510/IMM2510 in 1L NSCLC anticipated before end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177998,"accession_number":"0001789769-25-000024","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Instil Bio enters $100M at-the-market stock offering with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement with Jefferies LLC allows ATM sales of up to $100M in common stock.","Agent receives 3.0% commission on gross sales price per share sold.","Sales may be made directly on Nasdaq Capital Market; Company not obligated to sell.","Agreement terminates upon full sale or 10 trading days' notice from either party.","Prospectus supplement filed March 28, 2025 under effective S-3 registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177997,"accession_number":"0001789769-25-000012","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Instil Bio Q4 net loss $1.82/sh; cash $115.1M; AXN-2510 NSCLC data expected 1H2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss per share $1.82 in Q4, full year $11.39; non-GAAP $1.08 and $7.59 respectively.","Cash, equivalents, restricted cash and marketable securities $115.1M at Dec 31, 2024, down from $175.0M year-end 2023; runway beyond 2026.","Clinical data for AXN-2510 (PD-L1xVEGF bispecific) monotherapy in R/R NSCLC anticipated 1H2025; safety data across ~100 patients.","ImmuneOnco to initiate 1L NSCLC patient enrollment in China Phase 1b/2 trial of AXN-2510 plus chemo in Q2 2025; US trial expected before end of 2025.","R&D expenses $1.1M Q4 (vs $2.0M prior year); G&A $10.4M Q4; restructuring charges $0.3M Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177996,"accession_number":"0001789769-25-000003","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmuneOnco doses first patient in Instil's IMM2510 Phase 1b/2 NSCLC trial; data in 2H 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ImmuneOnco dosed first patient in combined-chemotherapy trial for advanced NSCLC in China.","Initial clinical data for 1L advanced NSCLC expected as early as second half of 2025.","Instil targets initiating U.S. first-line NSCLC trial of IMM2510 plus chemo in 2H 2025, subject to regulatory approvals.","CEO Bronson Crouch says positive data could enable a global registrational study in front-line NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194689,"accession_number":"0001789769-24-000106","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"Instil Bio subsidiary closes $85.6M term loan at 6.35% to refinance property debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan from Midland National Life Insurance Co., fixed 6.35% interest-only, 2-year term with 1-year extension option.","Proceeds used to repay all construction loans secured by Tarzana, CA facility (original June 2022 agreements).","Loan secured by first mortgage on property; generally non-recourse but with customary carveouts and full recourse for bankruptcy or unauthorized transfers.","Financial covenants: consolidated net worth ≥ $50M (excl. property) and minimum liquidity of $17.1M.","Prepayment penalty within first 12 months (make-whole); no penalty after."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194688,"accession_number":"0001789769-24-000100","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Instil Bio Q3 net loss $3.54/sh; cash $122.9M; licensed PD-L1xVEGF bispecific SYN-2510","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Licensed SYN-2510 (PD-L1xVEGF bispecific) and SYN-27M (CTLA-4 antibody) from ImmuneOnco for global ex-China rights.","Clinical data update for SYN-2510 monotherapy in China expected 1H 2025; Phase 1b/2 combo in NSCLC late 2024, TNBC 1H 2025 in China.","U.S. study of SYN-2510 in NSCLC targeted to start 2H 2025.","Cash, equivalents & securities $122.9M as of Sept 30, 2024 (down from $175.0M Dec 31, 2023); cash runway beyond 2026.","Q3 2024 net loss $3.54 per share vs $10.37 in Q3 2023; non-GAAP loss $2.55 vs $2.53."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210990,"accession_number":"0001628280-24-040396","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Instil Bio and ImmuneOnco outline global registrational strategy for SYN-2510 in NSCLC and TNBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Global registrational strategy for SYN-2510/IMM2510 in front-line NSCLC and TNBC announced.","Phase 1b/2 chemo combo in front-line NSCLC expected to start late 2024 in China; US IND submission for SYN-2510 targeted late 2024 for Phase 2 monotherapy in second-line NSCLC.","Phase 1b/2 chemo combo in front-line TNBC expected to start early 2025 in China; potential global Phase 3 trials after proof-of-concept.","US Phase 2 monotherapy trial in second-line NSCLC expected to support efficient enrollment of global Phase 3 studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210989,"accession_number":"0001628280-24-039726","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Instil Bio to close remaining UK operations, cut workforce, incur up to $5.5M in restructuring costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved restructuring plan to close Manchester, UK operations and eliminate remaining UK workforce.","Estimated aggregate restructuring costs up to $5.5M, including asset impairment ($2.2M), severance ($2.0M), and contract termination ($1.3M).","Workforce reduction expected to be substantially complete by end of 2024.","Charges are subject to assumptions; additional costs may arise not currently contemplated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210988,"accession_number":"0001789769-24-000090","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Instil Bio provides SYN-2510 program overview in investor presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished presentation detailing its SYN-2510 program as of August 2024.","No specific clinical data, milestones, or financial projections disclosed in the filing.","The program overview does not include any changes to previously disclosed guidance or plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210987,"accession_number":"0001789769-24-000082","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Instil Bio Q2 net loss $2.29/share; in-licenses two assets, leases facility to AstraZeneca","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $2.29 (GAAP), non-GAAP $1.57 for Q2 2024; improved from $2.87 and $2.03 in Q2 2023.","Cash, equivalents, marketable securities and long-term investments $152.6M as of June 30, expected runway beyond 2026.","In-licensed SYN-2510 (PD-L1xVEGF bispecific) and SYN-27M (ADCC-enhanced anti-CTLA-4) from ImmuneOnco for exclusive global rights outside Greater China.","Executed 15-year lease of cell therapy manufacturing facility to AstraZeneca; initial base rent >$7.5M annually escalating at 3%.","R&D expenses fell to $2.9M in Q2 2024 from $8.5M in Q2 2023; restructuring and impairment charges minimal."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210986,"accession_number":"0001789769-24-000077","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Instil Bio licenses bispecific and CTLA-4 antibodies from ImmuneOnco in deal up to $2.15B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SynBioTx (Instil subsidiary) gains exclusive license to IMM2510 (PD-L1/VEGF) and IMM27M (CTLA-4) outside Greater China.","ImmuneOnco receives $10M upfront, up to $50M near-term payments, plus up to $2.1B in milestones.","Royalties on net sales outside Greater China: single-digit to low double-digit percent.","SynBioTx can terminate for convenience on 180 days' notice; termination rights for breach or patent challenge.","ImmuneOnco retains development and commercialization rights within China, including Hong Kong, Macau, Taiwan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210985,"accession_number":"0001789769-24-000075","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Instil Bio leases Tarzana facility to AstraZeneca for ~15 years at $7.5M/yr initial rent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial term ~15 years from July 10, 2024 to July 31, 2039; two 5-year extension options.","Initial base rent $627,276/month ($7,527,312 annually) escalating 3% per annum.","Tenant has one-time option to terminate at 10th anniversary with termination fee.","Rent abatement during first year; Tenant also pays certain operating and tax expenses.","Tenant granted a right of first offer to purchase the leased premises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229463,"accession_number":"0001789769-24-000070","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Instil Bio stockholders elect two directors, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["R. Kent McGaughy, Jr. elected as Class III director with 4,499,758 votes for and 129,194 withheld.","Dr. Gwendolyn Binder elected as Class III director with 4,351,989 votes for and 276,963 withheld.","Stockholders ratified Deloitte & Touche as auditor for FY 2024: 5,718,919 for, 11,543 against, 6,627 abstentions.","Approximately 88.20% of outstanding shares (5,737,089 of 6,503,913) were present or represented by proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229462,"accession_number":"0001789769-24-000057","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Instil Bio reports Q1 net loss $3.74/share; cash runway beyond 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments of $161.5M at March 31, 2024; runway extends beyond 2026.","Net loss per share (GAAP) $3.74 vs $8.77 YoY; non-GAAP loss per share $2.39 vs $4.29.","R&D expenses fell to $7.3M from $20.7M; restructuring/impairment charges dropped to $4.3M.","Preparing potential investigator-initiated trial of FRα-CoStAR TIL in non-small cell lung cancer.","Company is exploring in-licensing or acquiring novel therapeutic candidates for unmet needs."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229461,"accession_number":"0001789769-24-000050","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jack B. Nielsen resigns from Instil Bio board; George Matcham appointed to Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack B. Nielsen resigned from the Board effective April 24, 2024 for personal reasons; not due to any disagreement.","George Matcham, Ph.D., existing board member, appointed to the Audit Committee to fill vacancy.","No other changes; resignation is routine and not related to company operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248019,"accession_number":"0001789769-24-000034","cik":1789769,"company_name":"Instil Bio, Inc.","ticker":"TIL","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Instil Bio reports Q4 net loss $1.99/share; ends ITIL-306 trial, closes UK facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $175.0M as of Dec 31, 2023, down from $260.9M a year earlier; runway expected beyond 2026.","Q4 2023 net loss $1.99/share (GAAP), $1.26/share non-GAAP; full year net loss $24.00/share.","R&D expenses fell to $2.0M in Q4 2023 from $20.7M in Q4 2022; restructuring/impairment charges totaled $72.0M for the year.","Strategic collaboration announced for FRα-CoStAR TIL in NSCLC in China; ITIL-306 clinical trial stopped.","Closed UK manufacturing facility; management exploring in-licensing/acquisition of novel therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":54798370.4078624,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}